The North America farm animal drugs market is expected to reach US$ 12,454.7 million by 2028 from US$ 7,848.8 million in 2021. The market is estimated to grow at a CAGR of 6.8% from 2021–2028.
Consumers are becoming increasingly aware and concerned about the welfare of animals raised for food. This has put pressure on suppliers to ensure that animals entering their systems are treated humanely. Measures are being taken for addressing such demand. Only one drug is approved in the US to control interdigital phlegmon (foot rot) pain in non-lactating cattle. Therefore, using medications for pain management in elective procedures, such as dehorning and castration, in cattle or analgesia in lactating dairy cows and pigs is considered an extra-label drug use. It is regulated as per the clarification on the use of veterinary drugs law. Flunixin, meloxicam, and ketoprofen are nonsteroidal anti-inflammatory drugs with supportive research on on-farm analgesia. Several products, such as local and regional anesthetics, opioids, and nonsteroidal anti-inflammatory drugs (NSAIDs), are available in the market to relieve pain in animals. Thus, such advancements are accelerating growth of the North America farm animal drugs market.
Some associations, such as the Canadian Cattlemen's Association, has called farmers to put cattle on maintenance rations rather than finishing rations to limit feedlot placements, coping with the closure of processing plants, and limited market capacities. Indeed, many farmers failed to obtain essential veterinary services, including routine health check-ins, drugs, vaccines, and testing and diagnostic tools. Thus, disease control of animals has become an additional challenge conflicting with animal welfare aspects. Unfortunately, the effect of COVID-19 on the activities related to animal healthcare is not restricted only on the farm-scale, but there are also national and international restrictions. The pandemic's impact on the livestock supply chain affected the local marketing process by reducing marketing opportunities, blocking of import/export activity, and lowering purchasing power, and consumers', demand (misconception regarding animal products safety and reduced consumers' income). All of these interruptions in the livestock supply chain put the producers (farmers) at risk of not being able to continue in the field. The limitation of movements and the disruption of national and international trade routes drive to a substantial decrease in vital livestock farming materials and facilities, such as feed materials, replacement stocks (e.g., day-old chicks, piglets, gilts, heifers, and semen straws), drugs and vaccines, feed additives, and other livestock farming inputs. Thus, Covid-19 has a negative impact on the market’s growth.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the farm animal drugs market. The North America farm animal drugs market is expected to grow at a good CAGR during the forecast period.
North America Farm animal drugs Market Revenue and Forecast to 2028 (US$ Million)
North America Farm Animal Drugs Market Segmentation
By Product Type
- Anti-Infective
- Parasiticides
- Anti-inflammatory
- Anesthetics
- Analgesics
- Hormones and Related Products
- Others
By Animal Type
By Route of Administration
- Oral
- Parenteral
- Topical
- Others
By Distribution Channel
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies and Drug Stores
- Others
By Country
- North America
- US
- Canada
- Mexico
Companies Mentioned
- PHIBRO ANIMAL HEALTH CORPORATION
- Zoetis Inc.
- Ceva
- Elanco
- Virbac
- INTAS PHARMACEUTICALS LTD.
- Alembic Pharmaceuticals Limited
- Boehringer Ingelheim International GmbH
- MSD Animal Health